title: Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
abstract: Despite anticonvulsant efficacy in animal models of generalized epilepsy, levetiracetam was not effective in the maximal subcutaneous PTZ model in mice and rats. Aim of this study was to assess the efficacy of levetiracetam (LEV) against submaximal, s.c. MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA). Thirty male Wistar rats (P42) were divided in three drug-treatment groups (10 rats in each group) as follows: valproic acid, levetiracetam, and controls. All animals were tested for seizure threshold at age P50. VPA (110 mg/kg) and LEV (108 mg/kg) were freshly dissolved in saline and injected i.p. in 2-3 ml/kg, 15 and 30 min, respectively, before pentylenetetrazol (PTZ) injection at the dose of 70 mg/kg. The average latency of the seizure type 3 (generalized clonic seizure with loss of righting reflexes) significantly differed between controls and the drug-treated animal groups (p < or = 0.02). The average duration of the seizure type 2 (threshold seizure) was significantly longer in both groups compared to controls (<0.02). In conclusion, LEV plays a role against seizures triggered by subcutaneous PTZ injection given at submaximal doses in rats, as demonstrated by a significant increase in duration of the seizure type 2 (threshold seizure).
authors.affiliation: Clinic of Child Neuropsychiatry, Second University of Naples, Via Pansini 5, Naples, Italy. giangennaro.coppola@unina2.it
authors.forename: Giangennaro
authors.initials: G
authors.lastname: Coppola
authors.forename: Salvatore
authors.initials: S
authors.lastname: Arcieri
authors.forename: Alfredo
authors.initials: A
authors.lastname: D'Aniello
authors.forename: Tullio
authors.initials: T
authors.lastname: Messana
authors.forename: Alberto
authors.initials: A
authors.lastname: Verrotti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Signoriello
authors.forename: Antonio
authors.initials: A
authors.lastname: Pascotto
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D003292:Convulsants / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004597:Electroshock; D004829:Epilepsy, Generalized / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D007279:Injections, Subcutaneous; D000077287:Levetiracetam; D008297:Male; D010433:Pentylenetetrazole / Q000008:administration & dosage; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D014635:Valproic Acid / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D003292:Convulsants; D000077287:Levetiracetam; D014635:Valproic Acid; D010433:Pentylenetetrazole; D010889:Piracetam